ReviewCurrent radiopharmaceuticals2025
Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.
Review in Current radiopharmaceuticals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Approaches to modeling cancer metastasis: from bench to bedside.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By integrating the sensitivity of nuclear medicine and the precision of nanotechnology, mankind can explore the very promising nuclear nanomedicine technology. Such integration enabled the imaging of biological processes at the molecular level which is a blessing to modern disease management. The present work is an effort to highlight the multifaceted applications of radiolabelled nanomaterials across various imaging modalities, formulation assessment, drug development, regulatory considerations, and therapeutic interventions. The present work highlights the application of radiolabelled nanomaterials for molecular imaging. The single-photon emission computed tomography (SPECT), positron emission tomography (PET); and hybrid multimodalities, along with their key features, are inherent parts of this discussion. The discussion continues with the assessment procedures of new formulations and their implications for drug delivery and the associated regulatory affairs. Cell tracking strategies that allow real-time monitoring of cellular behaviour
Indexed as
Identifiers
40304320What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.